Biovector Therapeutics

Biovector Therapeutics was a French biotechnology company specializing in the development of advanced drug delivery systems, specifically its proprietary Supramolecular BioVector (SMBV) technology. The SMBV platform utilized a polysaccharide core surrounded by a lipid bilayer to mimic the structure of natural viruses, facilitating the delivery of proteins, peptides, and nucleic acids. The company's primary focus was on mucosal vaccines and immunotherapy, with its lead program being an intranasal influenza vaccine. In 2002, Biovector Therapeutics was acquired by Flamel Technologies (now Avadel Pharmaceuticals) to integrate its delivery expertise with Flamel's Medusa and Micropump platforms. The acquisition allowed for the expansion of Flamel's portfolio into the vaccine and protein delivery markets. During its operation, Biovector established several high-profile collaborations with pharmaceutical companies to apply its delivery technology to various therapeutic candidates. The company was headquartered in Toulouse, France, and was backed by prominent European venture capital firms.